Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Akta Trimedika
Irmiya Rachmiyani
Fakultas Kedokteran, Universitas Trisakti, Jakarta, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
BENEFITS AND RISKS OF ULIPRISTAL ACETATE FOR UTERINE FIBROIDS Triasti Khusfiani; Yudhisman Imran; Irmiya Rachmiyani; Donna Adriani
Jurnal Akta Trimedika Vol. 2 No. 1 (2025): Januari 2025
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25105/aktatrimedika.v2i1.21724

Abstract

Uterine fibroids (FU) are often experienced by women of reproductive age or in their early menopause with therapy options involving surgical intervention such as hysterectomy. Ulipristal Acetate (UPA) is an oral drug from the selective progesterone receptor modulator (SPRM) class which has been proven to be effective in treating FU symptoms so that patients can maintain their fertility and their uterus. The PEARL I-IV clinical trials (PGL4001/UPA Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata) has proven the effectiveness of this drug in terms of reducing symptoms such as bleeding and pain, reducing fibroid volume, as well as its impact on the patient's quality of life. During ongoing clinical trials, the majority of side effects found were mild-moderate and reversible. In 2020, UPA was discontinued due to reports of the risk of DILI (drug induced liver injury), but after thorough investigation and considering its benefit and risk ratio for patients, UPA can be given again but its indication is limited to intermittent FU therapy with moderate to severe symptoms in women who has not reach menopause or when surgical procedures cannot be performed/have failed. Close monitoring of liver function is of course necessary.
Co-Authors Donna Adriani Triasti Khusfiani Yudhisman Imran